CFP and paroxysmal nocturnal hemoglobinuria: Using RBCs derived from PNH patients who are under eculizumab treatment, blocking properdin completely protected PNH type II and III RBCs from rH19-20-mediated lysis (Figure 3B), however eculizumab did not (Figure 3D).